EULAR 2026 at a glance
EULAR 2026 highlights a potential shift in rheumatology strategy from expanding therapeutic pathways toward evidence-based treatment sequencing. Competition is increasingly focused on organ-level differentiation, disease-modifying mechanisms, immune reset and the integration of artificial intelligence (AI) into clinical workflows.
LucidQuest examines the developments that could influence treatment positioning, clinical differentiation and competitive strategy across rheumatology.
📅 Build your schedule around the topics that matter most.
📥 Download the EULAR 2026_Preview_by_LucidQuest
EULAR 2026: Key Developments in Rheumatology
Lupus: Differentiation Across Organ Domains
Systemic lupus erythematosus (SLE) and lupus nephritis data will test whether FcRn, BAFF-R, CD20, TLR7/8, plasma-cell and interferon (IFN) strategies can demonstrate meaningful differentiation across organ domains.
These developments may influence how emerging therapies are positioned according to their clinical effects in different disease manifestations.
Sjögren’s Disease: Advancing Systemic Treatment Strategies
Ianalumab, telitacicept, nipocalimab and anifrolumab may help clarify whether systemic disease-modifying claims can extend beyond dryness-related endpoints.
The discussions will focus on the potential for broader systemic treatment differentiation in Sjögren’s disease.
Autoimmune Cell Therapy: Testing Durability and Safety
Obe-cel, rese-cel, universal CAR-T 19 and CD19 CAR-T approaches in rheumatoid arthritis (RA) will highlight the potential of cell therapy beyond refractory patient populations.
Durability and safety remain important considerations in assessing whether these approaches can support broader clinical use.
Psoriatic Arthritis and Axial Spondyloarthritis: Refining Treatment Sequencing
BE BOLD, sonelokimab and data involving JAK, IL-17A/F, IL-23 and TNF-targeted therapies may sharpen treatment sequencing decisions in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).
These developments could help clarify when switching therapeutic mechanisms may offer advantages over cycling within established treatment classes.
Rheumatology Competitive Landscape: Competitor and Industry Signals
AstraZeneca, GSK, UCB and Biogen: Lupus Treatment Strategies
Lupus sessions involving AstraZeneca, GSK, UCB and Biogen will address early intervention, prevention of organ damage, treat-to-target care and treatment decisions in patients of reproductive age.
These discussions will help frame the clinical priorities influencing lupus treatment strategies.
MSD and Boehringer Ingelheim: Interstitial Lung Disease and Fibrosis
Sessions involving MSD and Boehringer Ingelheim will focus on recognizing interstitial lung disease associated with systemic autoimmune rheumatic diseases (SARD-ILD) and systemic sclerosis (SSc-ILD).
High-resolution computed tomography (HRCT) monitoring, multidisciplinary team (MDT) workflows and intervention timing will be central considerations.
Bristol Myers Squibb and Cabaletta Bio: CAR-T and Immune Reset
CAR-T sessions involving Bristol Myers Squibb and Cabaletta Bio will keep immune reset visible as an emerging therapeutic approach in rheumatology.
However, durability and safety benchmarks remain unresolved and will be important for assessing future clinical positioning.
Novartis, Johnson & Johnson and UCB: Psoriatic Disease and Spondyloarthritis
Sessions involving Novartis, Johnson & Johnson and UCB will explore how inflammation control, pain, comorbidities and treat-to-target strategies influence therapeutic positioning in psoriatic disease and spondyloarthritis.
Artificial Intelligence and Machine Learning at EULAR 2026
AI-Enabled Imaging: Moving Toward Clinical Workflows
Thermography, ADMIRA MRI, ultrasound AI and salivary gland imaging will test whether objective assessments of inflammation can be incorporated into routine clinical workflows.
The key question is whether these technologies can support practical clinical decision-making beyond their technical capabilities.
Predictive Models: Earlier Detection and Longitudinal Monitoring
Electronic health record (EHR)-based detection, RA flare prediction, remission modeling and trial-emulation platforms could support earlier referral and longitudinal disease monitoring.
Their clinical value will depend on whether predictive performance can translate into practical implementation.
What We Are Watching After EULAR 2026
LucidQuest will monitor three competitive developments:
- Psoriatic arthritis differentiation: Whether BE BOLD supports a clinically useful differentiation claim based on joint outcomes, onset and IL-17A/F safety trade-offs.
- SLE and Sjögren’s treatment strategies: Whether emerging mechanisms demonstrate differentiation by organ domain, steroid-sparing effects, biomarkers and durability.
- AI implementation: Whether AI-focused sessions provide evidence of clinical implementation rather than model performance alone.
Download LucidQuest’s EULAR 2026 Preview Report
Download our EULAR 2026 preview report for deeper analysis of emerging rheumatology therapies, treatment sequencing, competitor positioning and AI-enabled clinical approaches.
📅 Build your schedule around the sessions that matter most.
📥 Download the EULAR 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
